- Home
- BCG vs ATOS Comparison
BCG vs ATOS Comparison
Compare BCG & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCG | ATOS |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 24.4M |
| IPO Year | 2025 | 2010 |
Fundamental Metrics
Financial Performance| Metric | BCG | ATOS |
|---|---|---|
| Price | $1.07 | $2.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 16.2K | ★ 93.6K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.50 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $187,144,000.00 | $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.50 | ★ N/A |
| Revenue Growth | ★ 10.80 | N/A |
| 52 Week Low | $0.95 | $0.53 |
| 52 Week High | $3.44 | $7.56 |
Technical Indicators
Market Signals| Indicator | BCG | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 56.60 |
| Support Level | $0.95 | $2.20 |
| Resistance Level | $1.67 | $3.04 |
| Average True Range (ATR) | 0.04 | 0.27 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 75.06 | 54.00 |
Price Performance
Historical ComparisonAbout BCG Binah Capital Group Inc.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.